XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Jun. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 118.4 $ 117.0
Marketable investment securities 46.0 33.7
Trade accounts receivable 94.8 89.5
Inventory 17.7 27.1
Assets held for sale 225.7 0.0
Prepaid taxes 18.6 108.4
Prepaid expenses and other current assets 17.7 13.7
Total current assets 538.9 389.4
Operating lease right-of-use assets 86.6 59.7
Long-term marketable investment securities 19.9 21.0
Property, plant, and equipment, net 43.2 40.7
Intangibles, net 426.8 576.5
Goodwill 240.1 329.2
Other assets 4.8 2.3
Total assets 1,360.3 1,418.8
Current liabilities:    
Accounts payable 28.5 20.5
Accrued liabilities 90.9 79.1
Current maturities of operating lease liabilities 12.7 13.6
Deferred revenues 22.6 32.7
Liabilities held for sale 12.2 0.0
Current portion of long-term debt 104.1 0.0
Total current liabilities 271.0 145.9
Unrecognized tax benefits 31.0 30.5
Long-term deferred taxes 58.2 71.3
Noncurrent operating lease liabilities 83.9 50.6
Long-term debt 0.0 224.8
Other long-term liabilities 13.8 14.7
Total liabilities 457.9 537.8
Commitments and contingencies
Stockholders’ equity:    
Common stock, 77.7 million and 75.4 million shares outstanding at June 30, 2021 and December 31, 2020, respectively 0.8 0.8
Additional paid-in capital 1,176.9 1,109.5
Accumulated other comprehensive loss (4.0) (2.3)
Accumulated deficit (271.2) (227.0)
Total Myriad Genetics, Inc. stockholders’ equity 902.5 881.0
Non-controlling interest (0.1) 0.0
Total stockholders' equity 902.4 881.0
Total liabilities and stockholders’ equity $ 1,360.3 $ 1,418.8